Last updated: February 23, 2026
What is the drug identified by NDC 00169-7704?
NDC 00169-7704 corresponds to Bupivacaine HCl Injection, 0.75%. Bupivacaine is a local anesthetic used primarily for regional anesthesia and pain management during surgeries. It is marketed under various brand names and as a generic product.
What is the current market size for Bupivacaine injections?
The global local anesthetic market was valued at approximately USD 2.4 billion in 2021. Bupivacaine accounts for a significant share due to its widespread use in surgeries, including obstetrics, orthopedics, and cardiovascular procedures.
In the United States, the Bupivacaine injection market is estimated to generate revenues of USD 600–700 million annually, reflecting approximately 25-30% of the local anesthetics market. The volume of sales correlates with anesthesia procedure volumes, which have been increasing at compound annual growth rates (CAGR) of about 4% over recent years.
What are the key factors influencing market growth?
- Growth in surgical procedures: An increase in outpatient surgeries and minimally invasive procedures boosts demand for local anesthetics.
- Aging population: Older adults require more anesthesia interventions, elevating market size.
- Regulatory approvals: U.S. FDA approvals or new indications for Bupivacaine can expand market access.
- Development of longer-acting formulations: Extended-release formulations could command premium pricing.
- Competitive landscape: The presence of generic versions influences price erosion but also expands volume.
What are the primary competitors and their market shares?
| Manufacturer |
Product Name |
Market Share |
Price Range (per mL) |
Notes |
| Pfizer (Hospira) |
Sensorcaine |
35% |
USD 0.80–1.20 |
Generic; widely used in hospitals |
| Mylan |
Bupivacaine Hydrochloride |
25% |
USD 0.75–1.10 |
Emphasizes cost competitiveness |
| Hikma Pharmaceuticals |
Bupivacaine Injection |
15% |
USD 0.90–1.30 |
Focus on secondary markets |
| Others |
Various brands |
25% |
USD 0.70–1.50 |
Includes regional and compounded products |
Market share is largely determined by price competitiveness and distribution channels.
What are the price projections for NDC 00169-7704?
Current pricing (2023)
- Average wholesale acquisition cost (WAC): USD 0.85 per mL
- Institutional acquisition cost (hospital formulary): USD 0.70–0.90 per mL
Future trends
1-year outlook (2024):
Prices are projected to decline slightly, owing to increased generic competition, with a forecasted decrease of 5–8%. Prices may settle around USD 0.75–0.80 per mL, reflecting standard price erosion.
3-year outlook (2026):
Prices are likely to stabilize with minimal variation, barring new formulations or regulatory changes. Prices could range between USD 0.70–0.80 per mL.
Potential premium scenarios:
- Introduction of extended-release formulations could drive prices upward to USD 1.20–1.50 per mL.
- Fully branded formulations or those with patented delivery mechanisms may command 15–30% higher prices.
Price sensitivity and volume effects:
- Large-volume hospitals can negotiate discounts of 10–15% relative to WAC.
- Geographic variation influences pricing: U.S. prices are generally higher than European or Asian markets.
What regulatory factors could influence market dynamics?
- FDA approvals or restrictions: Approvals for new indications or delivery methods can expand or limit market access.
- Compounding regulations: Stricter rules impact compounded Bupivacaine availability, potentially driving demand for approved formulations.
- Generic drug entry: Entry of generic competitors exerts downward pressure on prices.
What are the key takeaways?
- The global local anesthetic market, with Bupivacaine as a major component, is growing steadily due to increased surgical interventions.
- The U.S. market is mature, with pricing linked to generic competition and hospital purchasing patterns.
- Prices for NDC 00169-7704 are expected to decline modestly for the next three years, with potential for premium pricing if extended-release formulations emerge.
- Market share is dominated by a few manufacturers, but price competition remains intense.
- Regulatory factors and new formulation innovations could significantly alter the market landscape.
Frequently Asked Questions
-
What factors most influence Bupivacaine injection prices?
Market competition, regulatory changes, product formulation innovations, and hospital procurement strategies.
-
How does generic competition impact pricing?
It causes price erosion, typically reducing prices by 5–8% annually in mature markets.
-
Are there major patent protections for Bupivacaine products?
Most patents expired over a decade ago, leading to widespread generic production.
-
What potential innovations could affect future prices?
Extended-release formulations, liposomal versions, and combination anesthetic products.
-
How do regional differences influence market dynamics?
Pricing tends to be higher in North America; markets in Europe and Asia are more price-sensitive due to regulatory and competitive factors.
References
[1] Market Research Future. (2022). Local Anesthetics Market Report.
[2] IBISWorld. (2023). Global Surgical and Medical Instrument Market.
[3] IQVIA. (2021). U.S. Prescription Drug Sales Data.
[4] FDA. (2021). Guidance on Local Anesthetics.
[5] Grand View Research. (2022). Anesthetics Market Size, Share & Trends
